Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31543770 | 1.00 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3HRH3UTS2R | |
| Oxalic Acid SCHEMBL19742820 | 0.94 | SLC6A9 (0.40) | SLC6A4SLC6A2SLC6A3HRH3UTS2R | |
| SCHEMBL17880603 | 0.88 | AOC3 (0.42) | SLC6A4HRH3UTS2RSLC6A9 | |
| SCHEMBL31543765 | 0.88 | AOC3 (0.42) | SLC6A4HRH3UTS2RSLC6A9 | |
| SCHEMBL31543767 | 0.88 | UTS2R (0.45) | SLC6A4SLC6A2HRH3UTS2R | |
| SCHEMBL17880602 | 0.88 | UTS2R (0.45) | SLC6A4SLC6A2HRH3UTS2R | |
| SCHEMBL31543754 | 0.85 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL17880570 | 0.85 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL31543759 | 0.85 | KCNH2 (0.46) | SLC6A4SLC6A2HRH3 | |
| SCHEMBL17880592 | 0.85 | KCNH2 (0.46) | SLC6A4SLC6A2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093644-B2 | 3-[(Benzo[D][1,3]dioxolan-4-yl)-oxy]-3-arylpropylamine type compounds and applications thereof | NHWA PHARMA. CORPORATION (CN) | 2018-10-09 | — | — | US | claimed |
| US-20170369466-A1 | 3-[(BENZO[D][1,3]DIOXOLAN-4-YL)-OXY]-3-ARYLPROPYLAMINE TYPE COMPOUNDS AND APPLICATIONS THEREOF | NHWA PHARMA. CORPORATION (CN) | 2017-12-28 | — | — | US | claimed |
| US-10093644-B2 | 3-[(Benzo[D][1,3]dioxolan-4-yl)-oxy]-3-arylpropylamine type compounds and applications thereof | NHWA PHARMA. CORPORATION (CN) | 2018-10-09 | — | — | US | disclosed |
| US-20170369466-A1 | 3-[(BENZO[D][1,3]DIOXOLAN-4-YL)-OXY]-3-ARYLPROPYLAMINE TYPE COMPOUNDS AND APPLICATIONS THEREOF | NHWA PHARMA. CORPORATION (CN) | 2017-12-28 | — | — | US | disclosed |
| US-20170369466-A1 | 3-[(BENZO[D][1,3]DIOXOLAN-4-YL)-OXY]-3-ARYLPROPYLAMINE TYPE COMPOUNDS AND APPLICATIONS THEREOF | NHWA PHARMA. CORPORATION (CN) | 2017-12-28 | — | — | US | disclosed |
| WO-2016101898-A1 | 3-[(BENZO[D][1,3]DIOXOLANE-4-YL)-OXY]-3-ARYLANILINE TYPE COMPOUNDS AND APPLICATIONS THEREOF | 江苏恩华药业股份有限公司 | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093644-B2 | 3-[(Benzo[D][1,3]dioxolan-4-yl)-oxy]-3-arylpropylamine type compounds and applications thereof | TPH1, MAOA, MAOB | SLC6A4 7/4885SLC6A2 20/4885SLC6A3 6/4885 |
| US-20170369466-A1 | 3-[(BENZO[D][1,3]DIOXOLAN-4-YL)-OXY]-3-ARYLPROPYLAMINE TYPE COMPOUNDS AND APPLICATIONS THEREOF | TPH1, MAOA, MAOB | SLC6A4 7/4885SLC6A2 20/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.